Cerulean crashes after lead nano drug flubs its second PhII cancer study
Cerulean Pharma’s lead nanotech cancer drug has run into another stone wall in the clinic. The Waltham, MA-based biotech $CERU says that CRLX101 combined …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
